Table 5.

Adverse reaction features.

Characteristic	Prostanoid-naïve n = 6 (21.4%)	Transition n = 22 (78.6%)	Overall n = 28
Patients with adverse reaction	5 (83.3)	16 (72.7)	21 (75.0)
Adverse events (n)	22	59	81
Adverse reaction severity
Mild	6 (27.3)	16 (27.1)	22 (27.1)
Moderate	12 (54.6)	27 (45.8)	39 (48.1)
Severe	3 (13.6)	16 (27.1)	19 (23.5)
Not defined	1 (4.5)	0 (0.0)	1 (1.3)
Timing of symptom
Immediately	1 (4.5)	4 (6.8)	5 (6.2)
Days	4 (18.2)	24 (40.8)	28 (34.6)
Weeks	5 (22.8)	20 (33.8)	25 (30.7)
Months	9 (40.9)	11 (18.6)	20 (24.6)
Years	2 (9.1)	0 (0.0)	2 (2.6)
Not defined	1 (4.5)	0 (0.0)	1 (1.3)
Symptom setting
Dose increase	11 (50.0)	6 (10.2)	17 (21.0)
Initiation/transition only	2 (9.1)	6 (10.2)	8 (10.0)
Initiation/transition/  maintenance	0 (0.0)	23 (39.0)	23 (28.4)
Maintenance only	4 (18.2)	16 (27.1)	20 (24.6)
Other	5 (22.7)	8 (13.5)	13 (16.0)
Symptom duration
Transient	16 (72.7)	34 (57.6)	50 (61.7)
Persistent	6 (27.3)	23 (39.0)	29 (35.8)
Other	0 (0.0)	2 (3.4)	2 (2.6)
Symptom resolution
Partial	3 (13.6)	20 (33.9)	23 (28.5)
Complete	13 (59.2)	21 (35.6)	34 (41.9)
Not defined	6 (27.2)	18 (30.5)	24 (29.6)
Management
No change	11 (50)	24 (40.8)	35 (43.3)
Dose lowered	3 (13.6)	13 (22.0)	16 (19.8)
Uptitration rate slowed	7 (31.9)	15 (25.4)	22 (27.1)
Discontinued treprostinil  (patients)	1 (16.7)	4 (9.1)	5 (17.9)

Values are given as n (%).

The percent noted relates to the number of adverse reactions, not the number of patients affected except for “Patients with adverse reactions” and “Discontinued treprostinil,” which report the number of patients.

Adverse reactions that occurred during initial study period through 1 June 2017; includes initiation, transition, and maintenance.